Olaparib plus pembrolizumab shows promising results in BRCA mutated cancers
Olaparib plus pembrolizumab shows promising results in BRCA mutated cancers
Metastasis-directed radiotherapy shows good prognosis for oligometastatic kidney cancer
Circulating tumour DNA can guide adjuvant immunotherapy for mismatch repair-deficient tumours
Penpulimab in combination with chemotherapy for metastatic nasopharyngeal cancer shows positive results
Addition of pembrolizumab to standard care shows promising results in advanced head and neck cancer
EGFR shows to be a promising therapeutic target in NF1 mutant melanoma
ELCC 2025: Latest in EGFR positive NSCLC
Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC
Taletrectinib superior to crizotinib in ROS1-positive non-small cell lung cancer
Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patients with stage IIIa(N2) NSCLC
Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced NSCLC
Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC